Harvard, Dana-Farber License Screening Platform to Acetylon (GenomeWeb News)

8 March 2010, 7:30 am

NEW YORK (Genomeweb News) – Harvard University and the Dana-Farber Cancer Institute today said that they have licensed exclusive rights to a high-throughput screening and lead optimization platform for histone deactylase (HDAC) inhibitor compounds to Acetylon Pharmaceuticals.... Read More »

More Topics from "News"

• Tribune wins fairness award (Chicago Tribune)
• Tribune wins fairness award for Clout Goes to College expose (Chicago Tribune)
• BYU ranked most popular school in nation (KSL Salt Lake City)
• Community celebrates swim team's 16th big splash (Worcester Telegram & Gazette)
• BYU first, Harvard second on U.S. News & World Report's enrollment-percentage list (Deseret News)
• BYU ranks most popular university in U.S. (Provo Daily Herald)
• ZenBio Licenses Metabolic Cell Line from Harvard (GenomeWeb News)
• Gurus Go To Harvard (Forbes)
• Harvard University and Dana-Farber Cancer Institute Grant Acetylon Exclusive License to Breakthrough Discovery ... (Business Wire via Yahoo! Finance)